2020 - A Year Full Of Potentials, page-92

"15x cheaper,"

Oh, so CYP has a product on sale? Elsewise, how could it have a price to compare with, to be cheaper with?

I must have missed the phase 3 trial, the successful results, the FDA approval, the sales.

So exactly what is this cheaper product? What does it cost?

By the way, "LOL" is not an answer. ASIC writes whole articles warning against what you cite as evidence that CYP is a better investment than MSB.

MSB has already arrived where CYP hopes its 3 phase 2 trials might get it in several years time.

I am not coming here to bore people with pointless comparisons between a successful company with carefully selected world-class management and an outfit just coming into the clinic. There is no comparison.

My real concern is with possible misdirection to genuine potential investors who may not be aware of the long road to success and pitfalls of biotech.

By all means Sector and others, trumpet the possible advantages of CYP technology but don't stretch the bow beyond breaking point by claiming this makes CYP a good investment yet. It takes years and as yet undemonstrated good results. Whatever the generation of technology. This is biotech.

All you've got is hope. MSB has product. I share the CYP hope but it won't get my money yet.